Table 1.

Publication characteristics and citation rates for included trials of thrombolytics for stroke

Trial	Year published	Patients enrolled	Location	Journal	Intervention	Jadad score	Result	Total citations	Citations per year
NINDS [11]	1995	624	US	NEJM	IV tPA	5	Positive	6622	330
ECASS III [12]	2008	821	Europe	NEJM	IV tPA	5	Positive	2458	335
ECASS [13]	1995	620	Europe	JAMA	IV tPA	5	Neutral	2138	106
ECASS II [14]	1998	800	Europe, Australia, NZ	Lancet	IV tPA	5	Neutral	1768	102
EPITHET [15]	2008	101	Australia, NZ, Belgium, UK	Lancet Neurology	IV tPA	5	Neutral	561	72
IST-3 [16]	2012	3035	Europe, Canada, Mexico, Australia	Lancet	IV tPA	3	Neutral	380	104
ATLANTIS B [17]	1999	613	US, Canada	JAMA	IV tPA	5	Negative	820	51
ATLANTIS A [18]	2000	142	US	Stroke	IV tPA	5	Negative	276	18
PROACT II [19]	1999	180	US, Canada	JAMA	IA pro-urokinase	3	Positive	2287	142
DIAS [20]	2005	104	Europe, Australia, Singapore	Stroke	IV desmoteplase	5	Positive	749	69
DIAS-2 [21]	2009	193	Australia, Europe, US, Canada, China, Singapore	Lancet Neurology	IV desmoteplase	5	Neutral	332	49
MELT [22]	2007	114	Japan	Stroke	IA urokinase	3	Neutral	282	34
ASK [23]	1996	340	Australia	JAMA	IV streptokinase	5	Negative	328	17
MAST-E [24]	1996	310	Europe	NEJM	IV streptokinase	5	Negative	421	22
MAST-I [25]	1995	622	Europe	Lancet	IV streptokinase	3	Negative	551	27

IA intra-arterial, IV intravenous, JAMA Journal of the American Medical Association, NEJM New England Journal of Medicine, NZ New Zealand, tPA alteplase, US United States, UK United Kingdom